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Background. e dose of alcohol used in EUS-CPN is not standardized. e objective was to compare the safety of 20mL alcohol
versus 10mLalcohol during EUS-CPN for patientswith pancreatic cancer-related pain.Methods. 20 patientswere selected to receive
10mL or 20mL of alcohol during EUS-CPN. Followup was done at baseline, 24 hours, and weekly. Health-related quality of life
(HRQoL) was assessed at baseline, week 2, week 4, and every 4 weeks thereaer until pain returned. Results. ere were no major
complications in both groups. Minor self-limited adverse eﬀects were seen in 6 (30%) subjects and included lightheadedness in
1 (5%), transient diarrhea in 2 (10%), and transient nausea and vomiting in 3. Pain relief was similar in both groups: 80% in the
10mL group and 100% in the 20mL group (𝑃𝑃 = 0.21). e mean (± SD) duration of pain relief in the 10mL and 20mL groups was
7.9 ± 10.8 and 8.4 ± 9.2 weeks, respectively. 30% of patients in each group had complete pain relief. Conclusions. EUS-CPN using
20mL of alcohol is safe. Similar clinical outcomes were seen in both groups. Further investigations to con�rm these �ndings are
warranted.
1. Introduction
One of the main concerns of patients with pancreatic cancer
is pain [1]. For patients with pancreatic cancer, pain has a
negative impact on quality of life (HRQoL) [2]. Pain will be
present in a third of patients at the time of diagnosis, 30% to
50% undergoing treatment, and up to 90%with advanced dis-
ease [3–10]. Aer surgery for pancreatic cancer from 60% to
84% of patients reportedmoderate-to-severe pain [11].While
opioids are commonly used to relieve pain, their adverse side
eﬀects such as sedation, constipation, nausea, and vomiting
have a negative impact on quality of life [3]. Celiac plexus
neurolysis is not associated with these adverse eﬀects and
may improve survival among unresectable pancreatic cancer
patients [5]. Although endoscopic ultrasound-guided celiac
plexus neurolysis (EUS-CPN) does not have the side eﬀects
of opioids, it is not free of risks [12, 13]. Acute spinal cord
infarction has been reported aer EUS-CPN [13].
e amount of alcohol used in EUS-CPN ranges from
2 to 20mL of alcohol [14–18]. ere are no randomized
studies that compare the safety of varying amounts of alcohol
in celiac plexus neurolysis. We hypothesized that 20mL of
alcohol was safe in EUS-CPN. Onset of HRQoL and survival
were also examined.
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2. Methods
is study was approved by the Institutional Review Board
at Indiana University Medical Center. Consecutive patients
with known or suspected unresectable pancreatic cancer and
pain were enrolled. Written informed consent to participate
in this study was obtained from all patients enrolled. Patients
were excluded if they had the following: previous CPN
(endoscopic or percutaneous), an implanted pain relieving
device, or an arterial abdominal aneurysm. Patients were
selected to receive 20mL of 0.75% bupivacaine followed by
10mL or 20mL of alcohol for EUS-CPN. Opioid use was
not a prerequisite for entry into this study. Pain relief was
de�ned as a pain score less than or equal to 4, or at least a 30%
decrease in the pain score compared to baseline pain without
an increase in pain medication usage.
2.1. EUS-CPN Procedure. EUS-CPN is de�ned as injection of
a neurolytic agent into the celiac plexus area or directly into
celiac ganglia. Aer providing informed consent, subjects
were sedated with intravenous fentanyl, midazolam, and/or
Propofol. A 22-gauge hollow Echotip Ultra needle (Cook
Medical, Winston-Salem, NC, USA) was passed through the
working channel of the echoendoscope, through the poste-
rior wall of the stomach and directly into the celiac ganglia
(Figures 1(a) and 1(b)) when visualized or anterior to the
celiac trunk. A 5mL sterile saline-�lled syringe was loaded
onto the needle and was used to “test” the position of the
needle tip. rough the needle 20mL of 0.75% bupivacaine
was injected followed by 10mL or 20mL of 98% alcohol.
If celiac ganglia were visualized, they were directly injected
until the ganglia borders were blurred. When celiac ganglia
were not sonographically identi�ed, the needle was targeted
to the origin of the celiac artery takeoﬀ within 2 to 3mm.e
medication is administered in the same sequential fashion.
Aer the EUS-CPN procedure, each patient was observed
for at least one hour in the recovery room. Each patient
received 1000mL of intravenous �uids and antibiotics. Oral
antibiotics were prescribed for three days. Prior to discharge
each patient was assessed by the physician.
2.2. Followup. Baseline pain medication use and pain scores
were documented for each patient. Each patient was called
at 24 hours and weekly by a blinded research coordinator.
Followup continued until the patient reported a return of
their pain to baseline or died. Patients rated pain using a
numeric rating scale (NRS) that ranges from 0 to 10 where
0 is “no pain” and 10 is “worst pain.” During each phone
interview, patients were also asked to quantify their use of
pain medications. During each phone interview, the subject’s
pain was assessed using the brief pain inventory (BPI).
e BPI is a three question survey that rates intensity of
pain (severity) and interference of pain with mood, physical
activity, work, social activity, relations with others, sleep, and
enjoyment of life [19, 20]. Two HRQoL instruments, EORTC
QLQ-30 and EORTC PAN-26, were administered during
phone interviews at baseline, week 2, week 4, and every 4
weeks thereaer until the subject reported a return of their
T 1: Patient characteristics.
10mL alcohol 20mL alcohol P value
Gender 0.65
Male 5 4
Female 5 6
Mean (SD) age 66 (14) 63 (10) 0.5
Race 0.3
Caucasian 9 10
African American 1 0
Location in pancreas 0.41
Head 3 4
Uncinate 1
Body 4 1
Tail 0 1
Multiple 3 3
Immediate complications 0.11
None 8 4
Lightheadedness 1
Diarrhea 1 5
Nausea/vomiting 0 1
Ganglia injection 5 5 1
Adjuvant radiation 4 2 0.61
Adjuvant chemotherapy 6 7 0.87
ED visit prior EUS-CPN∗ 4 5 0.81
∗Subjects who visited the emergency department for pain control prior to
study entry.
pain to baseline or died. e date of death was documented
for each subject.
2.3. Statistical Methods. e frequency of complications was
calculated. Complete response was de�ned as a pain score of
zero without an increase in pain medication usage. Kaplan-
Meier estimates of duration of pain relief were calculated.
Health-related quality of life (HRQoL) scores were sum-
marized for each patient. Patients who died while still
experiencing pain relief are censored from our calculation of
pain-free survival. Patients who did not achieve pain relief
within the �rst four weeks of followup are assigned zero for
duration of pain relief and were not be censored. e overall
survival is calculated from the time of EUS-CPN.
3. Results
Patient characteristics are demonstrated in Table 1. e
characteristics of pain relief in each group are demon-
strated in Table 2. Among patients who received adjuvant
chemotherapy and/or radiation, the median (range) duration
of pain relief was 2.6 (0–32) weeks. Among patients who
did not receive adjuvant chemotherapy and/or radiation the
median (range) duration of pain relief was 2 (0–32) weeks.
Pain scores are shown in Table 3. Four of 20 (20%) subjects
(2 in each group) had pain relief that lasted over 16 weeks.
Characteristics of complete responders (patients who had
complete pain relief) are shown in Table 4. ere were no
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T 2: Characteristics of pain relief.
10mL alcohol 20mL alcohol P value
Total subjects 10 10
Number of subjects who had ganglia injected 5 5 1
Pain relief 8 (80%) 10 (100%) 0.21
Median (range) onset of pain relief (days) 1 (1–14) 1 (1–14)
Mean (SD) onset of pain relief (days) 4.3 (6.0) 4.2 (5.5) 0.81
Median (range) duration of pain relief (weeks) 3.0 (0–32) 3.5 (2–30)
Mean (SD) duration of pain relief (weeks) 7.9 (10.8) 8.4 (9.2) 0.9
SD: standard deviation.
(a) (b)
F 1: (a) EUS-CPN with direct injection into the celiac ganglia. (b) EUS image of direct celiac ganglia injection.
deaths during the phone interview followup period of this
study. Among the 10 patients who had direct injection of
celiac ganglia, the median (range) duration of pain relief was
3 (0–32) and 3 (2–30) weeks for the 10mL and 20mL groups,
respectively, (𝑃𝑃 = 0.69). In patients who did not have direct
injection of celiac ganglia, the median (range) duration of
pain relief 3 (2–8) and 1 (1–14) for the 10mL and 20mL
alcohol groups, respectively, (𝑃𝑃 = 0.19). A Kaplan Meier
survival curve is shown in Figure 2.
3.1. Quality of Life. HRQoL at the week 4 of followup is
shown inTable 5. Scores directly correlatedwith pain relief on
multiple measures. Minor adverse eﬀects seen in the 10mL
group included transient diarrhea in 1 and lightheadedness
in 1. Minor adverse eﬀects seen in the 20mL group included
transient diarrhea in 5 and nausea and vomiting in 1.
3.2. Complications. erewereminor self-limited postproce-
dure adverse eﬀects in 6 subjects including lightheadedness
in 1 (5%), transient diarrhea in 2 (10%), and transient nausea
and vomiting in 3 (15%). Only subject in the 20mL group
required an emergency room visit for pain control at week 2.
ere were no complications of bleeding or paralysis.
4. Discussion
ere were no major complications seen with the 20mL of
98% alcohol group compared to the 10mL group. During
the EUS-CPN procedure all patients received a combination
of fentanyl, versed, and propofol for sedation which likely
explains the absence of pain in the recovery room. We found
that EUS-CPN with 20mL of alcohol compared to 10mL
of alcohol was safe. However, we also noted that clinical
outcomes of the two groups were similar with respect to
overall pain relief (100% in 20mL group versus 80% in 10mL
group), weekly pain scores, onset of pain relief, duration
of pain relief, and proportion of complete responders. is
suggests that 20mL alcohol during EUS-CPN may not
provide signi�cant pain relief despite its safety. A statistically
signi�cant diﬀerence is not observed between the two groups,
however, as our study was a pilot study. A larger prospective
study is warranted to con�rm our �ndings.
We also noted an equal number of complete responders
in each group. Two thirds of these complete responders in
each group had direct injection of celiac ganglia.is suggests
that direct visualization and injection of celiac ganglia may
improve the accuracy of EUS-CPN. e overall eﬃcacy,
however, of EUS-CPN is likely explained by the diﬀuse spread
of alcohol in the celiac regionwhich likely explains this result.
With respect to pancreatic pain, digestive symptoms,
nausea, and vomiting, relatively better HRQoL scores were
seen in the 20mL group. is �nding has not previously
been reported, and a larger prospective study is necessary for
con�rmation. ere is a subtle trend in improved survival
in the 20mL group. Survival in general may be related to
pain relief and may re�ect the patient�s ability to perform
daily activities of living and have better nutrition. A larger
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T 3: Pain scores over time.
Time 10mL alcohol 20mL alcohol
N Mean SD % relief∗ N Mean SD % relief∗
Baseline 10 5.9 2.81 10 5.5 3.06
24 hours 10 2.9 1.79 80% 9 3.6 3.5 67%
Week 1 8 3.75 3.28 50% 10 3.6 2.5 60%
Week 2 8 3.88 2.9 63% 8 3.13 3.27 75%
Week 3 8 3.13 2.85 75% 8 1.88 2.17 88%
Week 4 4 2 1.83 100% 5 2.2 2.17 100%
Week 5 4 2.75 0.5 100% 3 2 1.73 100%
Week 6 3 1 1.73 100% 2 2 2.83 100%
NRS: numeric rating scale (0–10), SD: standard deviation, ∗pain relief as de�ned by a 30% reduction in pain scores without an increase in pain medication
consumption.
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F 2: Survival in subjects by randomization.e survival curve
shows the length of survival in days from the EUS-CPN procedure.
e slashed line represents subjects in the 20mL alcohol group, and
the straight line represents subjects in the 10mL alcohol group.
prospective study, however, is necessary to con�rm these
observations.
It has been reported that patients with pancreatic cancer
have lower pain scores and pain medication consumption
up to 16 weeks aer EUS-CPN [15, 21]. In 2006 the precise
identi�cation and injection of celiac ganglia during EUS-
CPN were reported in 16 of 22 (73%) patients [22]. In 2008
eﬃcacy and safety of directly injected celiac ganglia during
EUS-CPN were reported in 17 patients with unresectable
pancreatic cancer and pain [16]. At 2 and 4 weeks, 94%
of subjects reported pain relief as “complete,” or “par-
tial” [16]. Likewise, percutaneous and intraoperative celiac
plexus neurolysis (CPN) have been performed with varying
concentrations (50% to 100%) and amounts (15 to 50mL)
T 4: Characteristics of complete responders∗.
Characteristics 10mL alcohol 20mL alcohol
N 3 3
Mean age (SD) 51 (10) 66 (10)
Number of subjects with ganglia
injected 2 2
Median (range) onset of pain relief
(days) 1 ( 1–14) 1 (1–14)
Median (range) duration of pain
relief (weeks) 23 (3–32) 8 (3–30)
Median (range) duration of
complete response (weeks) 17 (1–22) 11 (3–21)
∗Complete responders were subjects who had pain scores of zero.
of alcohol [23–27] with eﬃcacy ranging from 70% to 90%
[23]. e variable response rates may be attributed to lack of
targeted injection into ganglia [5, 23, 26, 28–30]. In a recent
meta-analysis of percutaneous CPN, pain relief was rated as
good to excellent in 89% aer 2 weeks, partial to complete in
90% at 3 months, and partial to complete in 70–90% at the
time of death [23].
In our study minor self-limited postprocedure adverse
eﬀects were seen in a third of subjects including tran-
sient lightheadedness, diarrhea, nausea, and vomiting. Our
experience is similar to previous reports of adverse eﬀects
including diarrhea (17%), postural hypotension (1%), and
postprocedure-related abdominal pain (9%) [14, 31]. In
a report by Levy and colleagues, 7 of 17 patients (36%)
experienced pain exacerbation in the recovery room which
lasted 2.2 days [16]. Procedure-related transient abdominal
pain was noted in 9% of subjects who did not have direct
injection of celiac ganglia [14]. ere have been 2 reports of
major complications occurring aer EUS-CPB using steroids
for chronic pancreatitis including death aer an arterial pseu-
doaneurysm hemorrhage [32], and a peripancreatic abscess
developed 5 days aer EUS-CPB treated with intravenous
antibiotics [33]. A recent report of acute spinal cord infarc-
tion following EUS-CPN was attributed to 24mL of a 1 : 5
mixture of bupivacaine 0.25% with epinephrine and alcohol
(5mL into a celiac ganglia, and 19mL into the celiac trunk
area) [13]. In this patient with pancreatic adenocarcinoma of
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T 5: Quality of life scores at 4 weeks.
10mL alcohol 20mL alcohol
N mean SD N mean SD
Higher score is better
Physical functioning 4 63.3 11.5 4 43.3 42.3
Role functioning 4 58.3 21.5 4 29.2 47.9
Emotional functioning 4 62.5 28.5 4 56.3 41.6
Cognitive functioning 4 50 23.6 4 45.8 45.9
Social functioning 4 62.5 21 4 58.3 41.9
Global health status/QoL 4 54.2 16 4 47.9 23.9
Lower score is better
Fatigue 4 50 14.3 4 66.7 24
Nausea/vomiting 4 33.3 27.2 4 25 21.5
Pain 4 33.3 0 4 58.3 28.9
Dyspnea 4 16.7 33.3 4 50 43
Insomnia 4 16.7 19.2 4 25 50
Appetite loss 4 50 19.2 4 66.7 38.5
Constipation 4 16.7 19.2 4 33.3 27.2
Diarrhea 4 16.7 19.2 4 25 31.9
Financial problems 4 33.3 27.2 4 50 57.7
Higher score is better
PANCPAIN 4 54.2 21 4 60.4 26.7
DIGSYPTOMS 4 50 19.2 4 70.8 28.5
ALTBOWELHAB 4 79.2 16 4 58.3 39.7
HEPATIC 4 80.6 5.6 4 75 19
BODYIMAGE 4 70.8 21 4 41.7 50
SATHEALTHCARE 4 83.3 19.2 4 87.5 16
SEXUALITY 4 54.2 31.5 4 50 57.7
Overall 4 62.5 9 4 59.9 17.1
SD: standard deviation, dyspnea: shortness of breath, PANCPAIN: pan-
creatic pain, DIGSYPTOMS: digestive symptoms, ALTBOWLHAB: altered
bowel habits, HEPATIC: hepatic/liver abnormalities, BODYIMAGE: body
image, SATHEALTHCA: satisfaction with health care, SEXUALITY: sexual
function.
the head, the procedure resulted in paraplegia. is incident
lends to support that targeted injection of the celiac ganglia
is preferred, as the spinal artery can be injured during EUS-
CPN.
Lillemoe and colleagues demonstrated improved survival
aer intraoperative CPN (20mL of 50% alcohol) in a double-
blinded randomized placebocontrolled study of 139 subjects
with unresectable pancreatic cancer [5]. A survival bene�t
was not seen, however, with percutaneous CPN (20mL 100%
alcohol) in patients with unresectable pancreatic cancer [26].
e main limitation of our study is the size. In our pilot
study we have demonstrated preliminary evidence that EUS-
CPN 20mL 98% alcohol appears safe. Injection of ganglia
appears to improve accuracy of EUS-CPN and possibly the
duration of pain relief. A larger prospective trial is warranted
to con�rm our �ndings and further understandhow to exam-
ine the potential predictors of adjuvant therapy (chemother-
apy, radiation, or both) and direct ganglia injection (versus
injection into the celiac region) on the clinical outcomes of
pain relief, quality of life, and survival.
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